Veravas
Company

Last deal

$4M

Amount

Convertible Note

Stage

19.02.2020

Date

1

all rounds

$4M

Total amount

General

About Company
Veravas develops high-value solutions for accurate diagnosis of devastating diseases.

Industry

Sector :

Subsector :

Keywords :

Also Known As

Sanguine Technologies

founded date

01.01.2017

Number of employees

Company Type

For Profit

Last funding type

Convertible Note

IPO status

Private

Description

Their medical products are designed to improve laboratory medicine by identifying, removing, and measuring select substances from patient samples, reducing the effects of complex interferences and detecting low-abundance biomarkers. Veravas is transforming laboratory diagnostics by making early detection of disease possible in any sample type, including saliva, and bringing high-value tests to market in areas such as neurological diseases, cancer, cardiovascular, and infectious disease.